中国临床药学杂志

目的观察艾普拉唑7 d三联疗法及10 d序贯疗法根除幽门螺杆菌(Hp)的临床疗效。方法 142例经电子胃镜、RUT检查证实Hp阳性的慢性胃炎患者,随机分成3组。A组予艾普拉唑5 mg+阿莫西林克拉维酸钾0.914 g+呋喃唑酮0.1g,bid,疗程7 d;B组予艾普拉唑5 mg+阿莫西林克拉维酸钾0.914 g,疗程5 d,继之艾普拉唑5 mg+克拉霉素0.5 g+呋喃唑酮0.1g,疗程5 d,共计10 d,每天均给药2次;C组予埃索美拉唑20 mg+阿莫西林克拉维酸钾0.914 g+呋喃唑酮0.1 g,bid,疗程7 d。疗程结束4周后行¹⁴C-尿素呼气试验(¹⁴C-UBT),观察Hp根除率、症状缓解率及不良反应发生情况。结果 A、B、C组患者症状缓解率比较差异无统计学意义(P>0.05);Hp根除率分别为60%、58.54%和55.26%,经检验P均>0.05。3组患者均无明显不良反应发生。结论 3组用药方案虽能达到良好的症状缓解率,但Hp根除率均未超过60%,低于理想标准。

AIM To evaluate the Helicobacter pylori(Hp) eradication in 7-day triple therapeutic regimen and 10- day sequential therapy with ilaprazole.METHODS A total of 142 Hp-positive patients with chronic gastritis were randomly divided into 3 groups:group A,one-week triple therapeutic regimen with ilaprazole 5 mg,amoxicillin and clavulanate potassium 0.914 g and furazolidone 0.1 g bid;group B,10-day sequential therapy with ilaprazole 5 mg bid and amoxicillin and clavulanate potassium 0.914 g bid for 5 d,followed by ilaprazole 5mg bid + clarithromycin 0.5 g bid + furazolidone 0.1 g bid for 5 d;group C,one-week triple therapy with esomeprazole 20 mg,bid,amoxicillin and clavulanic acid potassium 0.914 g and furazolidone 0.1 g bid.RESULTS There was no statistical difference in the symptom remission rate and the Hp eradication rate between the 3 groups.The Hp eradication rate was 60%,58.54%and 55.26% respectively.CONCLUSION The 7-day triple therapeutic regimen and 10-day sequential fherapy with ilaprazole or esomeprazole is safe,but not effective in treatment of Hp infection.